Metsera

Metsera Dividend Coverage

Delisted

Dividend Coverage Ratio of Metsera (MTSR) as of Nov 4, 2026.

Dividend Coverage

-

Last updated:

Dividend Coverage Ratio of Metsera is 2026 - . Dividend Coverage Ratio of Metsera was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Metsera Stock analysis

What does Metsera do? Metsera Inc. is a clinical stage biopharmaceutical company based in New York City, operating in the Health Care sector with a focus on Biotechnology. The company develops next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides for treating obesity and related conditions. Utilizing its proprietary MINT peptide library, HALO half-life extension platform, and MOMENTUM oral delivery system, Metsera has a pipeline including MET-097i, MET-233i, and MET-224o, targeting various obesity treatments with differentiated approaches. Listed on 31 January 2025, the company employs 82 staff. Metsera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Metsera stock

On Eulerpool you can find the complete historical development of Dividend Coverage Ratio Metsera since 2006 – with annual values, charts, and detailed analysis.

The dividend coverage ratio measures how many times dividends can be covered by net income. Higher coverage suggests more sustainable dividend payments.

Dividend Coverage Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Coverage Ratio's Metsera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — Metsera

All Key Metrics — Metsera